News | November 24, 2009

Chronic Total Occlusion Catheter System Cleared in Europe

The CrossBoss and Stingray CTO catheters.

November 24, 2009 – European CE mark clearance was granted this week for BridgePoint Medical’s coronary and peripheral chronic total occlusion (CTO) crossing system comprised of the CrossBoss CTO Crossing Catheter and the Stingray CTO Re-Entry System.

The National Heart, Lung and Blood Institute (NHLBI) estimates CTOs are found in about one-third of patients who undergo angiography. Interventional cardiologists are currently unable to broadly treat patients with CTOs due to the procedurally challenging and advanced nature of the disease. For these patients, alternatives include bypass surgery or pharmacologic therapy.

“We have seen many attempts to implement new tools for the treatment of chronic coronary occlusions over the years, but until now none of them have provided any advantage over the current treatment of using specialty guide wires,” said Gerald Werner, M.D., Ph.D., professor at the Klinikum Darmstadt in Darmstadt, Germany. “This system is the first to provide a new option for the frequent situation when our guide wires do not reach the vessel beyond the occlusion. The BridgePoint system makes it possible to find the true vessel lumen and conclude the treatment successfully.”

The company said its disposable catheter system does not require the use of expensive and cumbersome capital equipment and uses techniques that are common in interventional medicine.

The CrossBoss and Stingray are indicated in the European Union for adults with coronary or peripheral artery disease, age 18 and older. The devices are contraindicated for use in cerebral vasculature.

In a prospective clinical trial conducted in the European Union and a post-market registry conducted primarily in South America, the BridgePoint System was 67-85 percent successful in placing an interventional guide wire beyond a chronic total coronary occlusion. Complications with the system were similar to general PCI and stenting.

The BridgePoint devices are currently under clinical investigation in the United States and are not commercially available for treating CTOs.

For more information: www.bridgepointmedical.com

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init